抗体偶联药物在卵巢癌中的研究进展
Research Progress of Antibody-Drug Conjugates in Ovarian Cancer
摘要: 卵巢癌致死率高，是严重威胁女性生命健康的妇科恶性肿瘤，大多数晚期卵巢癌患者最终不可避免的进入铂耐药阶段。由于铂耐药患者对各种化疗的反应较差，预后欠佳，铂耐药卵巢癌的治疗面临着巨大的挑战。抗体偶联药物(Antibody-drug Conjugate, ADC)是由靶向特异性抗原的单克隆抗体与小分子细胞毒性药物通过连接子连接而成的一类药物，已在血液恶性肿瘤和乳腺癌、非小细胞肺癌等实体瘤中有了成熟的应用。随着FDA加速批准Mirvetuximab Soravtansine治疗铂耐药复发卵巢癌，ADC类药物在卵巢癌治疗中也有了更多的研究和应用。本文阐述了ADC在卵巢癌中的主要临床研究进展。
Abstract: Ovarian cancer has a high mortality rate and is a serious threat to women’s health. Most patients with advanced ovarian cancer inevitably enter the platinum-resistant stage. Due to the poor response of platinum-resistant patients to various chemotherapies and poor prognosis, the treatment of platinum-resistant ovarian cancer faces huge challenges. Antibody-drug conjugates (ADCs) are a class of drugs composed of monoclonal antibodies targeting specific antigens and small molecule cytotoxic drugs linked by a linker. They have been successfully applied in hematological malignancies and solid tumors such as breast cancer and non-small cell lung cancer. With the FDA’s accelerated approval of Mirvetuximab Soravtansine for the treatment of platinum-resistant recurrent ovarian cancer, ADCs have also received more research and application in the treatment of ovarian cancer. This article elaborates on the main clinical research progress of ADCs in ovarian cancer.
文章引用：武文璐, 邱春萍. 抗体偶联药物在卵巢癌中的研究进展[J]. 临床医学进展, 2025, 15(4): 1824-1831. https://doi.org/10.12677/acm.2025.1541126

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Kuroki, L. and Guntupalli, S.R. (2020) Treatment of Epithelial Ovarian Cancer. British Medical Journal, 371, m3773. [Google Scholar] [CrossRef] [PubMed]
[3] Salani, R., Khanna, N., Frimer, M., Bristow, R.E. and Chen, L. (2017) An Update on Post-Treatment Surveillance and Diagnosis of Recurrence in Women with Gynecologic Malignancies: Society of Gynecologic Oncology (SGO) Recommendations. Gynecologic Oncology, 146, 3-10. [Google Scholar] [CrossRef] [PubMed]
[4] Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al. (2014) Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The Aurelia Open-Label Randomized Phase III Trial. Journal of Clinical Oncology, 32, 1302-1308. [Google Scholar] [CrossRef] [PubMed]
[5] Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[6] Fasih, S., Welch, S. and Lohmann, A.E. (2024) Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers. Current Oncology, 31, 7088-7106. [Google Scholar] [CrossRef] [PubMed]
[7] Vankemmelbeke, M. and Durrant, L. (2016) Third-Generation Antibody Drug Conjugates for Cancer Therapy—A Balancing Act. Therapeutic Delivery, 7, 141-144. [Google Scholar] [CrossRef] [PubMed]
[8] Sato, S., Shoji, T., Jo, A., Otsuka, H., Abe, M., Tatsuki, S., et al. (2024) Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer. Cancers, 16, Article 2545. [Google Scholar] [CrossRef] [PubMed]
[9] Tolcher, A., Hamilton, E. and Coleman, R.L. (2023) The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers. Cancer Treatment Reviews, 116, Article 102546. [Google Scholar] [CrossRef] [PubMed]
[10] Hafeez, U., Parakh, S., Gan, H.K. and Scott, A.M. (2020) Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25, Article 4764. [Google Scholar] [CrossRef] [PubMed]
[11] Matulonis, U.A., Lorusso, D., Oaknin, A., Pignata, S., Dean, A., Denys, H., et al. (2023) Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study. Journal of Clinical Oncology, 41, 2436-2445. [Google Scholar] [CrossRef] [PubMed]
[12] Moore, K.N., Angelergues, A., Konecny, G.E., García, Y., Banerjee, S., Lorusso, D., et al. (2023) Mirvetuximab Soravtansine in Frα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine, 389, 2162-2174. [Google Scholar] [CrossRef] [PubMed]
[13] Alvarez Secord, A., Lewin, S.N., Murphy, C.G., Cecere, S.C., Barquín, A., Gálvez-Montosa, F., et al. (2025) The Efficacy and Safety of Mirvetuximab Soravtansine in Frα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase II PICCOLO Trial. Annals of Oncology, 36, 321-330. [Google Scholar] [CrossRef] [PubMed]
[14] Gilbert, L., Oaknin, A., Matulonis, U.A., Mantia-Smaldone, G.M., Lim, P.C., Castro, C.M., et al. (2023) Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 170, 241-247. [Google Scholar] [CrossRef] [PubMed]
[15] Richardson, D.L., Moore, K.N., Vergote, I., Gilbert, L., Martin, L.P., Mantia-Smaldone, G.M., et al. (2024) Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer. Gynecologic Oncology, 185, 186-193. [Google Scholar] [CrossRef] [PubMed]
[16] Moore, K.N., O’Malley, D.M., Vergote, I., Martin, L.P., Gonzalez-Martin, A., Malek, K., et al. (2018) Safety and Activity Findings from a Phase 1b Escalation Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Carboplatin in Patients with Platinum-Sensitive Ovarian Cancer. Gynecologic Oncology, 151, 46-52. [Google Scholar] [CrossRef] [PubMed]
[17] Oaknin, A., Fariñas-Madrid, L., García-Duran, C., Martin, L.P., O’Malley, D.M., Schilder, R.J., et al. (2023) Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha (FOLRα) Antibody Drug Conjugate (ADC), Safety and Efficacy in a Broad Distribution of FOLRα Expression in Patients with Recurrent Epithelial Ovarian Cancer (OC): Update of STRO-002-GM1 Phase 1 Dose Expansion Cohort. Journal of Clinical Oncology, 41, 5508. [Google Scholar] [CrossRef] 
[18] Nishio, S., Yunokawa, M., Matsumoto, K., Takehara, K., Hasegawa, K., Hirashima, Y., et al. (2022) Safety and Efficacy of Morab-202 in Patients (PTS) with Platinum-Resistant Ovarian Cancer (PROC): Results from the Expansion Part of a Phase 1 Trial. Journal of Clinical Oncology, 40, 5513-5513. [Google Scholar] [CrossRef] 
[19] Li, N., Gong, J., Zhang, J., Liu, D., Chen, Y., Zhang, Y., et al. (2024) 787P First-In-Human, Phase I Study of CBP-1008, a First-in-Class Bi-Specific Ligand Drug Conjugate (Bi-XDC), in Patients with Advanced Solid Tumors. Annals of Oncology, 35, S589. [Google Scholar] [CrossRef] 
[20] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the Destiny-PanTumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, D., Wang, K., An, R., Yu, G., Zhang, K., Wang, D., et al. (2024) 715MO Safety and Efficacy of Sacituzumab Tirumotecan (sac-TMT) in Patients (pts) with Previously Treated Advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a Phase II Study. Annals of Oncology, 35, S548. [Google Scholar] [CrossRef] 
[22] Song, Z., Chen, L., Dang, Q., Tang, D., Liu, T., Wang, L., et al. (2024) 717MO SHR-A1921 in Platinum-Resistant Ovarian Cancer (PROC): Data from a First-in-Human (FIH) Phase I Study. Annals of Oncology, 35, S549. [Google Scholar] [CrossRef] 
[23] Lheureux, S., Alqaisi, H., Cohn, D.E., Chern, J., Duska, L.R., Jewell, A., et al. (2022) A Randomized Phase II Study of Bevacizumab and Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Refractory Ovarian Cancer NCI Trial#10150. Journal of Clinical Oncology, 40, 5514-5514. [Google Scholar] [CrossRef] 
[24] Liu, Y., Li, G., Yang, R., Huang, Y., Luo, S., Dang, Q., et al. (2024) The Efficacy and Safety of RC88 in Patients with Ovarian Cancer, Non-Squamous-Non-Small-Cell Lung-Carcinoma and Cervical Cancer: Results from a First-in-Human Phase 1/2 Study. Journal of Clinical Oncology, 42, 5551-5551. [Google Scholar] [CrossRef] 
[25] Richardson, D., Hamilton, E., Barve, M., Anderson, C., Taylor, S., Lakhani, N., et al. (2022) Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076). Gynecologic Oncology, 166, S48. [Google Scholar] [CrossRef] 
[26] Richardson, D., Concin, N., Hays, J., Fidalgo, J.A.P., Pothuri, B., Banerjee, S., et al. (2024) UPLIFT (ENGOT-OV67/GOG-3048): Results from the Phase II Trial of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 190, S56. [Google Scholar] [CrossRef] 
[27] Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., et al. (2018) Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin (DNIB0600A) Compared with Pegylated Liposomal Doxorubicin in Patients with Platinum-Resistant Ovarian Cancer in a Randomized, Open-Label, Phase II Study. Annals of Oncology, 29, 917-923. [Google Scholar] [CrossRef] [PubMed]
[28] Moore, K.N., Birrer, M.J., Marsters, J., Wang, Y., Choi, Y., Royer-Joo, S., et al. (2020) Phase 1b Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin (DNIB0600A) in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Gynecologic Oncology, 158, 631-639. [Google Scholar] [CrossRef] [PubMed]
[29] Meric-Bernstam, F., Naito, Y., Gaillard, S., Shimoi, T., Chung, V., Davis, A.A., et al. (2024) 606O Initial Results from a First-in-Human Study of the B7-H4-Directed Antibody-Drug Conjugate (ADC) AZD8205 (Puxitatug Samrotecan) in Patients with Advanced/Metastatic Solid Tumors. Annals of Oncology, 35, S485-S486. [Google Scholar] [CrossRef] 
[30] Perez, C.A., Henry, J.T., Lakhani, N., Call, J.A., Hamilton, E.P., Colon-Otero, G., et al. (2023) 660MO First-in-Human Study of SGN-B7H4V, a B7-H4-Directed Vedotin ADC, in Patients with Advanced Solid Tumors: Preliminary Results of a Phase I Study (SGNB7H4V-001). Annals of Oncology, 34, S464-S465. [Google Scholar] [CrossRef] 
[31] Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., et al. (2016) Phase I Study of Safety and Pharmacokinetics of the Anti-Muc16 Antibody-Drug Conjugate DMUC5754A in Patients with Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. Annals of Oncology, 27, 2124-2130. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, J., Burris, H., Wang, J.S., Barroilhet, L., Gutierrez, M., Wang, Y., et al. (2021) An Open-Label Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 163, 473-480. [Google Scholar] [CrossRef] [PubMed]
[33] Nguyen, T.D., Bordeau, B.M. and Balthasar, J.P. (2023) Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15, Article 713.

为你推荐